A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: BL-B01D1; Drug: Irinotecan; Drug: paclitaxel; Drug: docetaxel Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
Conditions: Non Small Cell Lung Cancer Interventions: Drug: D-1553 Tablet; Drug: Docetaxel injection Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
Conditions: Gastric Cancer Interventions: Drug: Docetaxel for injection (Albumin-bound); Drug: Taxotere (docetaxel) Sponsors: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Conditions: Triple Negative Breast Cancer Interventions: Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Docetaxel; Drug: Carboplatin; Procedure: Breast Surgery; Drug: Capecitabine Sponsors: University of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Conditions: Prostate Cancer Interventions: Drug: Darolutamide; Drug: Darolutamide matched placebo; Radiation: Radiotherapy; Drug: Zoladex 3.6Mg Implant; Drug: Zoladex LA; Drug: Decapeptyl sustained release 22.5 mg; Drug: Decapeptyl sustained release 11.25 mg; Drug: Depo-Eligard 45 mg; Drug: Depo-Eligard 22.5 mg; Drug: Depo-Eligard 7.5 mg; Drug: Firmagon 120 MG Injection; Drug: Firmagon 80 MG Injection; Drug: Docetaxel Sponsors: Cancer Research Antwerp; Bayer; Veracyte, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Study of KK2269 in Adult Participants With Solid Tumors
Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Non Small Cell Lung Cancer Interventions: Drug: KK2269; Drug: Docetaxel Sponsors: Kyowa Kirin, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Conditions: Advanced Solid Tumor Interventions: Drug: FT825; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Bendamustine; Drug: Docetaxel; Drug: Cisplatin; Drug: Cetuximab Sponsors: Fate Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Conditions: Breast Neoplasm Female Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Inetetamab; Drug: Pyrotinib Sponsors: Wang Ouchen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Precise Neoadjuvant Chemoresection of Low Grade NMIBC
Conditions: Bladder Cancer; Non-muscle Invasive Bladder Cancer; Low-risk Interventions: Drug: Epirubicin; Drug: Mitomycin; Drug: Gemcitabine; Drug: Docetaxel Sponsors: University of Bern; Spitalzentrum Biel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Conditions: Squamous Cell Carcinoma of the Head and Neck; Oropharynx; Human Papillomavirus Viruses; Drug Therapy; Cancer Vaccine Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: PRGN-2009 Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
A Phase II Study of SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
Conditions: SBRT Interventions: Combination Product: SBRT+chemoimmunotherapy Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
Drug Screening Using IMD in Bladder Cancer
Conditions: Muscle Invasive Bladder Urothelial Carcinoma Interventions: Device: Implantable Micro-Device; Drug: Methotrexate; Drug: Carboplatin; Drug: Avelumab; Drug: Paclitaxel; Drug: Vinblastine; Drug: Gemcitabine/Cisplatin I; Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab; Drug: Gemcitabine/Cisplatin II; Drug: Cisplatin; Drug: Nivolumab; Drug: Pembrolizumab; Drug: Gemcitabine/Carboplatin; Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin; Drug: Gemcitabine/Cisplatin/Nivolumab; Drug: Erdafitinib; Drug: Paclitaxel/Docetaxel/Ifosfamide; Drug: Gemcitabine; Drug: Gemcitabine/Carboplatin/Nivolumab; Drug: Enf...
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
A Study of TQB2930 for Injection Monotherapy or Combination Chemotherapy in Patients With Recurrent/Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer; Recurrent Breast Cancer Interventions: Drug: TQB2930 for injection; Drug: Docetaxel injection Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: KC1036; Drug: Irinotecan; Drug: Docetaxel; Drug: S-1 Sponsors: Beijing Konruns Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Adebrelimab Combined with Bevacizumab and Docetaxel Sponsors: The First Affiliated Hospital of Xinxiang Medical College Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2023 Category: Research Source Type: clinical trials
